STAs evaluate single technologies within a single condition. The company provides a submission detailing the clinical effectiveness and estimating the cost-effectiveness of the intervention.
SCHARR-TAG critiques the company’s submission and mathematical model and provides the NICE appraisal committee with exploratory analyses and corresponding cost-effectiveness values.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009
Lung cancer (non-small-cell, resected) - atezolizumab (adjuvant) (MA review of TA823) ID6324.
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6221].
Pembrolizumab for mesothelioma (malignant, pleural, unresectable, advanced, untreated) [ID4044].
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [ID6405].
Breast cancer (BRCA positive, HER2 negative, metastatic) - olaparib (after chemotherapy)(Review of TA762) [ID6336].
Sodium thiosulfate for preventing ototoxicity in people aged 1 month to 17 years with localised cancer having cisplatin chemotherapy [ID1001].
Sparsentan for treating primary IgA nephropathy [ID6308].
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115].
Sipavibart for preventing COVID-19 Evusheld 2.0 [ID6282].
Lung cancer (non-small cell, EGFR positive) - osimertinib (adjuvant) [Review of TA761] [ID5120].
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [ID4067].
Glioma (BRAF V600E, aged 1-17) - dabrafenib (with trametinib) [ID5104].
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged 25 and under (MA review of TA554) [ID6290].
Abaloparatide for treating osteoporosis in postmenopausal women [ID882].
Trastuzumab deruxtecan for treating HER2-Low metastatic or unresectable breast cancer after chemotherapy [ID3935].
Ritlecitinib for treating moderate to severe alopecia areata in people 12 years and over [ID4007].
Tixagevimab–cilgavimab for preventing COVID-19 Evusheld [ID6136].
Cabozantinib for previously treated differentiated thyroid cancer after radioactive iodine [ID4046].
Eptinezumab for preventing migraine [ID3803].
Pembrolizumab with trastuzumab and chemotherapy for untreated HER2- positive advanced gastric or gastro-oesophageal junction cancer [ID3742].
Ripretinib, after 3 therapies, for advanced gastrointestinal stromal tumours [ID3805].
177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840].
Slow-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis [ID3787].
KTE-X19 Autologous auto-CD19-transduced CD3+ cells for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia in adults [ID1494].
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia [ID1083].
Nivolumab for treating resected high-risk invasive urothelial cancer [ID2694].
Alpelisib with fulvestrant for HR positive, HER2 negative, PIK3CA positive breast cancer (review of TA652) [ID3929].
Pembrolizumab in combination for untreated, locally advanced or metastatic, triple negative breast cancer [ID1546].
Dapagliflozin for treating chronic kidney disease [ID3866].
Adjuvant nivolumab for oesophageal cancer [ID1676].
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection [ID3835].
Risdiplam for treating spinal muscular atrophy in children and adults [ID1631].
Fedratinib for splenomegaly and symptoms in myelofibrosis [ID1501].
Ibrutinib for Waldenstrom's [ID3778].
Pembrolizumab for advanced/unresectable or metastatic urothelial cancer [ID1634].
Pembrolizumab with carboplatin and paclitaxel or nab-paclitaxel for untreated metastatic squamous non-small-cell lung cancer [ID1683].
Isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID1477].
Tafamidis for treating transthyretin amyloid cardiomyopathy [ID1531].
Gilteritinib for treating relapsed or refractory acute myeloid leukaemia [ID1484].
Crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older [ID1195].
Trifluridine–tipiracil for treating metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID1507].
Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab [ID1583].
Acalabrutinib for treating chronic lymphocytic leukaemia [ID1613].
Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-positive breast cancer [ID1412].
Atezolizumab in combination with bevacizumab for hepatocellular carcinoma [ID1655].
Clostridium botulinum neurotoxin type A for treating hypersalivation associated with neurological conditions [ID1150].
Pentosan polysulfate sodium for treating bladder pain syndrome [ID1364].
Olaparib for maintenance treatment of BRCA-mutated ovarian, fallopian tube and peritoneal cancer after response to initial platinum-based chemotherapy [ID1124].
Pembrolizumab with carboplatin and paclitaxel for untreated squamous non-small-cell lung cancer [ID1306].
Blinatumomab for treating B-precursor, minimal residual remission acute lymphoblastic leukaemia [ID1036].
Sodium zirconium cyclosilicate for treating hyperkalaemia [ID1293].
Trastuzumab emtansine for locally adcanced or metastatic HER2 positive breast cancer after trastuzumab & a taxane (review of TA371) [ID1013].
Nusinersen for treating infant or child spinal muscular atrophy [ID1069].
Regorafenib after sorafenib, for treating unresectable hepatocellular carcinoma [ID991].
Sarilumab after TNFnhibitors for treating active rheumatoid arthritis [ID994].
Cx601 for treating complex perianal fistula in non-active or mildly-active luminal Crohn’s disease [ID960].
Baricitinib for treating moderate to severe rheumatoid arthritis [ID979].
Ponatinib for treating chronic myeloid leukaemia [ID671].
Tofacitinib for the treatment of moderate to severe active rheumatoid arthritis after failure of disease-modifying anti-rheumatic drugs [ID526].
Ibrutinib for treating Waldenstrom’s macroglobulinaemia [ID884].
Ibrutinib for treating relapsed or refractory mantle cell lymphoma [ID753].
Obinutuzumab in combination with bendamustine for treating rituximab-refractory follicular lymphoma [ID841].
Pertuzumab for treating early, HER 2 positive breast cancer [ID767].
Certolizumab pegol for treating rheumatoid arthritis following inadequate response to a TNF inhibitor [ID824].
Idiopathic pulmonary fibrosis - pirfenidone [ID837].
Adalimumab for treating moderate to severe hidradenitis suppurativa [ID812].
Cabazitaxel for the second-line treatment of hormone-refractory, metastatic prostate cancer [ID889].
Olaparib for the maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer with BRCA 1 or 2 mutations following response to prior platinum-based chemotherapy [ID735].
Hypercholesterolaemia (primary), dyslipidaemia (mixed) - evolocumab [ID765].
Vedolizumab for treating moderate to severe active Crohn’s disease after prior therapy [ID690].
Vedolizumab for ulcerative colitis [ID691].
Degarelix for the treatment of advanced hormone-dependent prostate cancer [ID590].
Sofosbuvir-ledipasvir for treating genotype 1 chronic hepatitis C [ID742].
Sipuleucel-T for the treatment of metastatic castrate-resistant prostate cancer [ID573].
Mepolizumab for treating severe eosinophilic asthma [ID798].
Trastuzumab emtansine for the treatment of locally advanced or metastatic HER2 - positive breast cancer after treatment with trastuzumab and a taxane [ID603].
Nalmefene for reduction of alcohol consumption in alcohol-dependent patients [ID660].
Rivaroxaban for the prevention of adverse outcomes in patients after the acute management of acute coronary syndrome [ID532].
Rituximab in combination with corticosteroids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID567].
Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar disorder in children and adolescents [ID305].
Pegloticase for the treatment of hyperuricaemia in people with symptomatic gout whose disease is refractory to conventional urate-lowering therapy, or in whom conventional urate-lowering therapy is contraindicated or not tolerated [ID521].
Alteplase for treating acute ischaemic stroke (review of technology appraisal guidance 122) [ID536].
Rivaroxaban for the treatment of deep vein thrombosis and secondary prevention of venous thromboembolism [ID437].
Bivalirudin for the treatment of ST-segment elevation myocardial infarction (10/09/01).
Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (10/24/01).
Golimumab for the treatment of rheumatoid arthritis after failure of previous disease-modifying antirheumatic drugs (08/118/01).
Mifamurtide for the treatment of osteosarcoma (08/77/01).
Cabazitaxel for the second-line treatment of hormone-refractory, metastatic prostate cancer (10/49/01).
Trabectedin for the treatment of relapsed ovarian cancer (08/212/01).
Bevacizumab in combination with oxaliplatin and either 5FU or capecitabine for the treatment of metastatic colorectal cancer (08/211/01).
Trabectedin for the treatment of advanced metastatic soft tissue sarcoma (08/92/01).
Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (08/03/01).
Febuxostat for the management of hyperuricaemia in people with gout (07/69/01).
Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (07/90/01).
Varenicline for smoking cessation (06/50/01).
Alteplase for the treatment of acute ischaemic stroke (06/51/01).
Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal (05/53/01).
Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal (05/51/01)
